BRPI0906785A2 - Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune - Google Patents

Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune

Info

Publication number
BRPI0906785A2
BRPI0906785A2 BRPI0906785-0A BRPI0906785A BRPI0906785A2 BR PI0906785 A2 BRPI0906785 A2 BR PI0906785A2 BR PI0906785 A BRPI0906785 A BR PI0906785A BR PI0906785 A2 BRPI0906785 A2 BR PI0906785A2
Authority
BR
Brazil
Prior art keywords
cell
compound
methods
pharmaceutical composition
autoimmune disease
Prior art date
Application number
BRPI0906785-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen M Condon
Matthew G Laporte
Yijun Deng
Susan R Rippin
Yu-Hua Lee
Thomas Haimowitz
Original Assignee
Tetralogic Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetralogic Pharm Corp filed Critical Tetralogic Pharm Corp
Publication of BRPI0906785A2 publication Critical patent/BRPI0906785A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0906785-0A 2008-01-24 2009-01-15 Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune BRPI0906785A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2323708P 2008-01-24 2008-01-24
PCT/US2009/031093 WO2009094287A1 (en) 2008-01-24 2009-01-15 Iap inhibitors

Publications (1)

Publication Number Publication Date
BRPI0906785A2 true BRPI0906785A2 (pt) 2015-07-14

Family

ID=40901405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906785-0A BRPI0906785A2 (pt) 2008-01-24 2009-01-15 Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune

Country Status (12)

Country Link
US (1) US20110288116A1 (enExample)
EP (1) EP2242362A4 (enExample)
JP (1) JP2011520770A (enExample)
KR (1) KR20100119768A (enExample)
CN (1) CN101951766A (enExample)
AU (1) AU2009206588A1 (enExample)
BR (1) BRPI0906785A2 (enExample)
CA (1) CA2712604A1 (enExample)
IL (1) IL207066A0 (enExample)
MX (1) MX2010007948A (enExample)
WO (1) WO2009094287A1 (enExample)
ZA (1) ZA201005618B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US20150190470A1 (en) * 2012-08-01 2015-07-09 Tetralogic Pharmaceuticals Corporation Combination therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
PL3083616T3 (pl) 2013-12-20 2021-12-06 Astex Therapeutics Limited Bicykliczne związki heterocykliczne i ich zastosowania w terapii
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
CN111247161B (zh) * 2017-11-13 2021-12-31 正大天晴药业集团股份有限公司 用作iap抑制剂的smac模拟物及其用途
CN113677339B (zh) * 2019-03-07 2023-08-01 正大天晴药业集团股份有限公司 Iap抑制剂与免疫检查点抑制剂的组合
US20220177453A1 (en) * 2019-05-10 2022-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystallization of smac mimic used as iap inhibitor and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523061A (ja) * 2004-01-16 2007-08-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｓｍａｃペプチドミメティクスおよびその使用法
AU2005231956B2 (en) * 2004-04-07 2009-11-05 Novartis Ag Inhibitors of IAP
US7674787B2 (en) * 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
CN103083644B (zh) * 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
US20070203749A1 (en) * 2005-08-09 2007-08-30 Sri Chunduru Business methods for compounds for treatment of proliferative disorders

Also Published As

Publication number Publication date
IL207066A0 (en) 2010-12-30
MX2010007948A (es) 2010-10-04
KR20100119768A (ko) 2010-11-10
EP2242362A4 (en) 2012-04-11
JP2011520770A (ja) 2011-07-21
ZA201005618B (en) 2011-04-28
AU2009206588A1 (en) 2009-07-30
WO2009094287A1 (en) 2009-07-30
CN101951766A (zh) 2011-01-19
US20110288116A1 (en) 2011-11-24
CA2712604A1 (en) 2009-07-30
EP2242362A1 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
BRPI0906785A2 (pt) Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune
BRPI1011612A2 (pt) composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, para tratar câncer, e para tratar uma doença autoimune.
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
IL233023A (en) Method of characterizing a cancer in a subject
IL222234A0 (en) Biomarkers for mdm2 inhibitors for use in treating disease
BRPI0817907A8 (pt) aparelho para administrar uma substância a um indivíduo
DK3192529T3 (da) Amatoksin-holdige terapeutiske celleoverflade-bindingskomponenter designet til tumorterapi
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0906467A2 (pt) forma de dose farmacêutica
BRPI1008598A2 (pt) composição farmacêutica para inalação
ES2397671T8 (es) Procedimiento para preparar voriconazol
BRPI0921220A8 (pt) cartucho, distribuidor farmacêutico para porções farmacêuticas sólidas, bem como empregos do cartucho e do distribuidor farmacêutico
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
ZA201102035B (en) Methods and formulations for treating chronic liver disease
BRPI1008664A2 (pt) comprimidos para a terapia de combinação
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BRPI0922983A2 (pt) comprimidos de desintegração rápida de capecitabina
PT2616201T (pt) Pastilhas para fresa de cambota e fresa que as utiliza
EP2063881A4 (en) COMPOSITION AND METHOD FOR THE EFFECTIVE AND SAFE ADMINISTRATION OF HALOPYRUVATE FOR THE TREATMENT OF CANCER
BRPI0917866A2 (pt) métodos para intensificar o metabolismo energético
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
BRPI0810091A2 (pt) Agentes fugicidas tópicos para tratar distúrbios ungueais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.